1	CLAIMS
2	What is claimed is:
3	
4	Claim 1. A biopolymer marker selected from the group
5	consisting of sequence ID (K)LFSDSPITVTVPVEVSR(K),
6	(K)LFDSDPITVTVPVEVSR(K), (R)ASSIIDELFQDR(F) or at least
7	one analyte thereof useful in indicating at least one
8	particular disease state.
C) 9	
10	Claim 2. The biopolymer marker of claim 1 wherein
W11	said disease state is predictive of Alzheimers disease.
12	
* 13	Claim 3. A method for evidencing and categorizing at
14 415	least one disease state comprising:
415	obtaining a sample from a patient;
16	conducting mass spectrometric analysis on said
17	sample;
18	evidencing and categorizing at least one biopolymer
19	marker sequence or analyte thereof isolated from said
20	sample; and,
21	comparing said at least one isolated biopolymer
22	marker sequence or analyte thereof to the biopolymer
23	marker sequence as set forth in claim 1;

wherein correlation of said isolated biopolymer

24

1 marker and said biopolymer marker sequence as set forth in 2 claim 1 evidences and categorizes said at least one 3 disease state. 4 5

Claim 4. The method of claim 3, wherein said step of evidencing and categorizing is particularly directed to biopolymer markers or analytes thereof linked to at least one risk of disease development of said patient.

(i)

Li. 12

7

The method of claim 3, wherein said step of evidencing and categorizing is particularly directed to biopolymer markers or analytes thereof related to the existence of a particular disease state.

The method of claim 3, wherein the sample is an unfractionated body fluid or a tissue sample.

63 116 17

18

19 The method of claim 3, wherein said sample 20 is at least one of the group consisting of blood, blood 21 products, urine, saliva, cerebrospinal fluid, and lymph.

22 23

24

Claim 8. The method of claim 3, wherein said mass spectrometric analysis is selected from the group

1	consisting of Surface Enhanced Laser Desorption Tonization
2	(SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS,
3	TOF-TOF, and ESI-Q-TOF or an ION-TRAP.
4	
5	Claim 9. The method of claim 3, wherein said
6	patient is a human.
7	
8	Claim 10. A diagnostic assay kit for determining
(1) 9	the presence of the biopolymer marker or analyte thereof
10	of claim 1 comprising:
11111	at least one biochemical material which is capable of
12	specifically binding with a biomolecule which includes at
* 13	least said biopolymer marker or analyte thereof, and
14	means for determining binding between said
15	biochemical material and said biomolecule;
16	whereby at least one analysis to determine a presence
17	of a marker, analyte thereof, or a biochemical material
18	specific thereto, is carried out on a sample.
19	
20	Claim 11. The diagnostic assay kit of claim 10,
21	wherein said biochemical material or biomolecule is
22	immobilized on a solid support.
23	
24	Claim 12. The diagnostic assay kit of claim 10

1	including:
2	at least one labeled biochemical material.
3	
4	Claim 13. The diagnostic assay kit of claim 10,
5	wherein said biochemical material is an antibody.
6	
7	Claim 14. The diagnostic assay kit of claim 12,
8	wherein said labeled biochemical material is an antibody.
9	
©10 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Claim 15. The diagnostic assay kit of claim 10,
11	wherein the sample is an unfractionated body fluid or a
12	tissue sample.
13	
14	Claim 16. The diagnostic assay kit of claim 10,
115	wherein said sample is at least one of the group
16	consisting of blood, blood products, urine, saliva,
17	cerebrospinal fluid, and lymph.
18	
19	Claim 17. The diagnostic assay kit of claim 10,
20	wherein said biochemical material is at least one
21	monoclonal antibody specific therefore.
22	
23	Claim 18. A kit for diagnosing, determining risk-
24	assessment, and identifying therapeutic avenues related to

The property of the state of the

24

1	a disease state comprising:
2	at least one biochemical material which is capable of
3	specifically binding with a biomolecule which includes at
4	least one biopolymer marker selected from the group
5	consisting of sequence ID (K)LFSDSPITVTVPVEVSR(K),
6	(K) LFDSDPITVTVPVEVSR(K) , (R) ASSIIDELFQDR(F) or at least
7	one analyte thereof related to said disease state; and
8	means for determining binding between said
9	biochemical material and said biomolecule;
10	whereby at least one analysis to determine a presence
11 11	of a marker, analyte thereof, or a biochemical material
12	specific thereto, is carried out on a sample.
13	
ù14 .⊍	Claim 19. The kit of claim 18, wherein said
15	biochemical material or biomolecule is immobilized on a
16	solid support.
17	
18	Claim 20. The kit of claim 18 including:
19	at least one labeled biochemical material.
20	
21	Claim 21. The kit of claim 18, wherein said
22	biochemical material is an antibody.
23	

Claim 22. The kit of claim 20, wherein said labeled

biochemical material is an antibody.

1 2

3 Claim 23. The kit of claim 18, wherein the sample is 4 an unfractionated body fluid or a tissue sample.

5

6 The kit of claim 18, wherein said sample 7 is at least one of the group consisting of blood, blood 8 products, urine, saliva, cerebrospinal fluid, and lymph.

09

Claim 25. The kit of claim 18, wherein said biochemical material is at least one monoclonal antibody specific therefore.

10 10 11 12 13 14 15 diagnosing, determining risk assessment, and identifying 16

17 18

19

20

21

22

Claim 27. The kit of claim 18, wherein said diagnosing, determining risk assessment, and identifying therapeutic avenues is carried out on multiple samples such that at least one analysis is carried out on a first sample and at least another analysis is carried out on a

Claim 26. The kit of claim 18, wherein said

therapeutic avenues is carried out on a single sample.

23 24 second sample.

1	Claim 28. The kit of claim 27, wherein said first
2	and second samples are obtained at different time periods.
3	
4	Claim 29. Polyclonal antibodies produced against a
5	marker sequence ID selected from the group consisting of
6	sequence ID (K)LFSDSPITVTVPVEVSR(K),
7	$\label{eq:continuous} (\texttt{K}) \texttt{LFDSDPITVTVPVEVSR}(\texttt{K}) \text{, } (\texttt{R}) \texttt{ASSIIDELFQDR}(\texttt{F}) \text{ or at least}$
8	one analyte thereof in at least one animal host.
C) 9	
⁽⁰⁾ 10	Claim 30. An antibody that specifically binds a
[4]11	biopolymer including a marker selected from the group
12	consisting of sequence ID (K) LFSDSPITVTVPVEVSR (K) ,
13	$\label{eq:continuous} (\texttt{K}) \texttt{LFDSDPITVTVPVEVSR} (\texttt{K}) \text{, } (\texttt{R}) \text{ASSIIDELFQDR} (\texttt{F}) \text{ or at least}$
114	one analyte thereof.
115	
16	Claim 31. The antibody of claim 30 that is a
17	monoclonal antibody.
18	
19	Claim 32. The antibody of claim 30 that is a
20	polyclonal antibody.
21	
22	Claim 33. A process for identifying therapeutic
23	avenues related to a disease state comprising:
24	conducting an analysis as provided by the kit of

16

17

18

19

20

21

22

23 24

1

claim 18; and

2 interacting with a biopolymer selected from the group 3 consisting of sequence ID (K)LFSDSPITVTVPVEVSR(K), 4

(K) LFDSDPITVTVPVEVSR(K), (R) ASSIIDELFQDR(F) or at least one analyte thereof;

5

6 whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of sequence ID (K)LFSDSPITVTVPVEVSR(K), (K) LFDSDPITVTVPVEVSR(K), (R) ASSIIDELFODR(F) or at least one analyte thereof.

Claim 35. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues developed include at least one avenue selected from a group consisting of 1)utilization and recognition of said biopolymer markers, variants or moieties thereof as direct therapeutic modalities, either alone or in conjunction with an effective amount of a pharmaceutically effective carrier; 2) validation of therapeutic modalities or disease 1 preventative agents as a function of biopolymer marker

2 presence or concentration; 3) treatment or prevention of a

3 disease state by formation of disease intervention

4 modalities; 4) use of biopolymer markers or moieties

thereof as a means of elucidating therapeutically viable

6 agents, 5)instigation of a therapeutic immunological

7 response; and 6) synthesis of molecular structures related

8 to said biopolymer markers, moieties or variants thereof

which are constructed and arranged to therapeutically

intervene in said disease state.

Claim 36. The process for identifying therapeutic avenues related to a disease state in accordance with claim 35, wherein said treatment or prevention of a disease state by formation of disease intervention modalities is the formation of biopolymer/ligand conjugates which intervene at receptor sites to prevent, delay or reverse a disease process.

18 19 20

21

22

5

C 9

16

17

Claim 37. The process for identifying therapeutic avenues related to a disease state in accordance with claim 35, wherein said means of elucidating

23 therapeutically viable agents includes use of a

24 bacteriophage peptide display library or a bacteriophage

1

antibody library.

2	
3	Claim 38. A process for regulating a disease state
4	by controlling the presence or absence of a biopolymer
5	selected from the group consisting of sequence ID
6	(K)LFSDSPITVTVPVEVSR(K), (K)LFDSDPITVTVPVEVSR(K),
7	$\mbox{(R)ASSIIDELFQDR(F)} \mbox{ or at least one analyte thereof.} \\$
8	
9	